Venture&Growth
Location
Heidelberg, Germany
Venture&Growth
All Portfolio items
See full Venture&Growth portfolio
mtm laboratories manufactures and commercializes in-vitro diagnostic tests for the analysis of cervical cancer. Worldwide, cervical cancer is the second most common cancer in women. mtm’s CINtec® technology detects a specific cellular biomarker (p16INK4a) and offers the potential for highly specific and accurate diagnosis of early-stage cervical cancer, even if it is without symptoms.
Since Gilde invested in mtm laboratories, the German company has clinically validated its diagnostic products and more than doubled its sales. mtm laboratories was acquired by Roche in 2011.
More mtm laboratories news
Study of CINtec® PLUS in the management of Pap negative but HPV positive women published
mtm laboratories Extends Series C Financing Round by EUR 7 Million ($9.7 Million)
MTM Laboratories – p16 Immuno-cytochemistry shows superior clinical performance to HPV testing
mtm’s CINtec® PLUS, delivers new solution to manage Pap negative but HPV positive women
mtm laboratories Announces the European Launch of CINtec(R) PLUS
MTM LABORATORIES – CINtec® p16 Histology test increases accuracy in diagnosing
GILDE HEALTHCARE II invests in mtm laboratories AG
Venture&Growth
Fire1
Irish MedTech company focused on remote monitoring of heart failure patients.
Venture&Growth
AM-Pharma
AM-Pharma is a Dutch biopharmaceutical company developing a biotherapeutic for the treatment of Sepsis Associated Acute Kidney Injury (SA-AKI).
Venture&Growth
Karius, Inc.
Karius is a U.S.-based diagnostic company that develops and commercializes an AI-based liquid biopsy test to diagnose serious infections in immunocompromised patients and other hospitalized patients. The company is commercial in the U.S. and provides strong potential for better care
